Skip to content

LSD research published in 2024

Page 3 of 5: studies 41 to 60 of 91, newest first. Back to the LSD overview

Studies

Brain Networks, Neurotransmitters and Psychedelics: Towards a Neurochemistry of Self-Awareness.

Current Neurology and Neuroscience Reports August 1, 2024 Daniel C Mograbi, Rafael S. Rodrigues, Bheatrix Bienemann et al. 12 citations

Self-awareness can be defined as the capacity of becoming the object of one's own awareness and, increasingly, it has been the target of scientific inquiry. Self-awareness has important clinical implications, and a better understanding of the neurochemical basis of self-awareness may help clarifying causes and developing interventions for different psychopathological conditions. The current...

The versatile binding landscape of the TAAR1 pocket for LSD and other antipsychotic drug molecules.

Cell Reports July 23, 2024 Kexin Jiang, You Zheng, Liting Zeng et al. 12 citations

Increasing global concerns about psychoactive substance addiction and psychotic disorders highlight the need for comprehensive research into the structure-function relationship governing ligand recognition between these substances and their receptors in the brain. Recent studies indicate the significant involvement of trace amine-associated receptor 1 (TAAR1) in the signaling regulation of the...

DOI: 10.1016/j.celrep.2024.114505 (opens in new tab) Full text (opens in new tab) Cp: neuroscience Psychiatric medications Neuroreceptors Psychopharmacology psychotropic drugs +2

Inter-individual variability in neural response to low doses of LSD.

Translational Psychiatry July 15, 2024 Nadia R. P. W. Hutten, Conny W.E.M. Quaedflieg, Natasha L. Mason et al. 16 citations

The repeated use of small doses of psychedelics (also referred to as "microdosing") to facilitate benefits in mental health, cognition, and mood is a trending practice. Placebo-controlled studies however have largely failed to demonstrate strong benefits, possibly because of large inter-individual response variability. The current study tested the hypothesis that effects of low doses of LSD on...

Magic of the Mushrooms: Effects of Psilocybin Decriminalization

Journal of Psychoactive Drugs July 10, 2024 Ashutosh Bhave 10 citations

In the past few years, psilocybin, a psychedelic compound found in "magic mushrooms" (psilocybin mushrooms), has undergone decriminalization in numerous cities across the US and has been legalized in Oregon and Colorado. Proponents of psilocybin decriminalization have emphasized its therapeutic potential in treating mental health disorders. Furthermore, psilocybin mushrooms are considered the...

DOI: 10.1080/02791072.2024.2376755 (opens in new tab) LSD MDMA Psilocybin reforms Policy change +8

IS PSYCHEDELIC TREATMENT OF MENTAL HEALTH DISORDERS READY FOR PRIME TIME?

Journal of Pakistan Psychiatric Society June 30, 2024 Nauman Ashraf 1 citation

Psychedelics, substances known to alter perception, mood, and consciousness, have been used across various cultures for centuries, often in religious ceremonies to facilitate spiritual experiences. Lysergic acid diethylamide (LSD) was used clinically from the 1950s until its ban in 1967. Recently, there has been a resurgence of interest in psychedelics for treating mental health disorders such...

Rapid and prolonged antidepressant and antianxiety effects of psilocybin, lysergic acid diethylamide, ayahuasca, and 3, 4-methylenedioxy-methamphetamine. A systematic review and meta-analysis of randomized controlled trials

medRxiv June 20, 2024 Dimy Fluyau, Vasanth Kattalai Kailasam, Neelambika Revadigar preprint

Abstract Background Hallucinogens attract research as alternatives to the commonly used medications to treat major depressive and anxiety disorders. Aims Assess hallucinogens’ efficacy for managing depressive and anxiety symptoms and evaluate their safety profiles. Method In five databases, we searched for randomized controlled trials of hallucinogens targeting depressive and anxiety symptoms....

DOI: 10.1101/2024.06.17.24308787 (opens in new tab) Full text (opens in new tab) Methamphetamine Antidepressant Meta-analysis Methylenedioxy +1

Spectral signatures of psilocybin, lysergic acid diethylamide (LSD) and ketamine in healthy volunteers and persons with major depressive disorder and treatment-resistant depression: A systematic review.

Journal of Affective Disorders June 15, 2024 Gia Han Le, Sabrina Wong, Sebastian Badulescu et al. 25 citations

Electrophysiologic measures provide an opportunity to inform mechanistic models and possibly biomarker prediction of response. Serotonergic psychedelics (SPs) (i.e., psilocybin, lysergic acid diethylamide (LSD)) and ketamine represent new investigational and established treatments in mood disorders respectively. There is a need to better characterize the mechanism of action of these agents. We...

DOI: 10.1016/j.jad.2024.03.165 (opens in new tab) Full text (opens in new tab) Electroencephalography Glutamatergic dissociatives Magnetoencephalography Serotinergic psychedelics +8

Is microdosing a placebo? A rapid review of low-dose LSD and psilocybin research

Journal of Psychopharmacology June 14, 2024 Vince Polito, Paul Liknaitzky 16 citations

Some recent research and commentary have suggested that most or all the effects reported by people who microdose psychedelics may be explained by expectations or placebo effects. In this rapid review, we aimed to evaluate the strength of evidence for a placebo explanation of the reported effects of microdosing. We conducted a PubMed search for all studies investigating psychedelic microdosing...

DOI: 10.1177/02698811241254831 (opens in new tab) Psilocybin Hallucinogen Placebo Expectancy theory +2

The mechanism of hallucinations caused by lysergic acid diethylamide

MedScien June 6, 2024 Chaoyi Fan, Jiayi Li, Shaohuan Yu

Lysergic acid diethylamide (LSD) is a semi-synthetic hallucinogen that induces intense hallucinogenic effects. There are various ways that hallucinations can occur, but classic psychedelics like LSD differ significantly in their effects from those caused by other means. The primary focus of current research is on activating 5-HT2A receptors within the serotonin system, which is essential for...

LSD-Forschung: Positive Effekte durch zeitgleiche Einnahme von MDMA?

Fortschritte der Neurologie · Psychiatrie June 1, 2024

Aufgrund seiner positiven subjektiven Wirkung hat Lysergsäurediethylamid (LSD) schon lange das psychiatrische Forschungsinteresse geweckt. Da aber neben gewünschten Effekten unter LSD auch Ängste keine Seltenheit sind, könnte die gleichzeitige Einnahme von MDMA (3,4-Methylendioxymethamphetamin) negative Effekte abfangen und die positiven verstärken. Straumann et al. sind dieser Hypothese...

Psilocybin, peyote, mescaline, and lysergic acid diethylamide (LSD) use in a nationally representative population by cancer history.

Journal of Clinical Oncology June 1, 2024 Amrit Baral, Yue Pan, Alberto J. Caban Martinez et al.

e22518 Background: Classic psychedelics (Peyote, Psilocybin, Mescaline, and LSD) are re-emerging in the oncology toolbox. Peyote is the oldest known psychedelic, yet underexplored in clinical research. Preclinical studies suggest its extract stimulates lymphocyte proliferation, kills tumor cells, and may regulate sleep. This study aims to estimate the prevalence of classic psychedelic use among...

Structural analysis of an lysergic acid diethylamide (LSD) analogue N-methyl-N-isopropyllysergamide (MiPLA): Insights from Rotamers in NMR spectra.

Drug Testing and Analysis June 1, 2024 Takuji Shoda, Genichiro Tsuji, Maiko Kawamura et al. 1 citation

Lysergic acid diethylamide (LSD) is a hallucinogenic compound that binds to and activates the serotonin 2A receptor and is classified as a controlled narcotic in Japan. Recently, MiPLA, an N-methyl-N-isopropyl derivative of LSD, has been detected in paper-sheet products in several countries. This study focuses on the synthesis of MiPLA and includes a comprehensive analysis involving structural...

Neural complexity is increased after low doses of LSD, but not moderate to high doses of oral THC or methamphetamine.

Neuropsychopharmacology June 1, 2024 Conor H. Murray, Joel Frohlich, Connor J Haggarty et al. 30 citations

Neural complexity correlates with one's level of consciousness. During coma, anesthesia, and sleep, complexity is reduced. During altered states, including after lysergic acid diethylamide (LSD), complexity is increased. In the present analysis, we examined whether low doses of LSD (13 and 26 µg) were sufficient to increase neural complexity in the absence of altered states of consciousness. In...

Perceived Risk of Trying Lysergic Acid Diethylamide in the United States from 2015 to 2019: Are Americans Assessing Lysergic Acid Diethylamide's Risk Profile More Favorably?

Psychedelic Medicine June 1, 2024 Brian S. Barnett, Akhil Anand, Elizabeth N. Dewey et al. 20 citations

Though lysergic acid diethylamide (LSD) use is rising in the United States amid expanding research into the therapeutic potential of psychedelics, little scholarly work exists on whether perceived risk of trying LSD (prLSD) is changing or factors influencing prLSD among the general public. Therefore, we sought to investigate changes in prLSD from 2015 to 2019 and identify characteristics...

DOI: 10.1089/psymed.2023.0027 (opens in new tab) Full text (opens in new tab) LSD Psychedelics hallucinogens Entheogens Harm reduction +5

A retrospective study of the characteristics and toxicology of cases of lysergic acid diethylamide (LSD)‐ and psilocybin‐related death in Australia

Addiction May 21, 2024 Shane Darke, Johan Duflou, Amy Peacock et al. 14 citations

Abstract Background and aims Lysergic acid diethylamide (LSD) and psilocybin are used as recreational drugs, and there is renewed interest in their clinical use. The current study aimed to (1) determine the circumstances of death and case characteristics of LSD‐ and psilocybin‐related death in Australia, 2000–23; and (2) determine the toxicological profile and major autopsy findings of these...

Suspension of Short‐lasting, Unilateral, Neuralgiform headache attacks with Conjunctival injection and Tearing (SUNCT) symptoms with ayahuasca and serotonergic psychedelics

Headache: The Journal of Head and Face Pain May 1, 2024 Jonathan A. Leighton, Cyril Petignat, Brian E. Mcgeeney 2 citations

Plain Language Summary A suicidal patient with Short‐lasting Unilateral Neuralgiform headache attacks with Conjunctival injection and Tearing (SUNCT) whose excruciating condition did not respond to various treatments discovered that ayahuasca, a psychoactive concoction used by indigenous populations of South America, caused his attacks to cease entirely. Inhaled N , N ‐dimethyltryptamine (DMT),...

Effective Connectivity of Thalamocortical Interactions Following d-Amphetamine, LSD, and MDMA Administration.

Biological Psychiatry: Cognitive Neuroscience and Neuroimaging May 1, 2024 Mihai Avram, Felix Müller, Katrin H. Preller et al. 13 citations

While the exploration of serotonergic psychedelics as psychiatric medicines deepens, so does the pressure to better understand how these compounds act on the brain. We used a double-blind, placebo-controlled, crossover design and administered lysergic acid diethylamide (LSD), 3,4-methylenedioxymethamphetamine (MDMA), and d-amphetamine in 25 healthy participants. By using spectral dynamic causal...

A Brief Historical Overview of Psychedelic Research.

Biological Psychiatry: Cognitive Neuroscience and Neuroimaging May 1, 2024 Mark A. Geyer 30 citations

Classical serotonergic psychedelics such as lysergic acid diethylamide or the naturally occurring compounds psilocybin and mescaline produce profound changes in mood, thought, intuition, sensory perception, the experience of time and space, and even the experience of self. Research examining psychedelic compounds has had a complex and turbulent evolution. Many cultures throughout the world have...

Microdosing Psychedelics: Current Evidence From Controlled Studies.

Biological Psychiatry: Cognitive Neuroscience and Neuroimaging May 1, 2024 Robin J Murphy, Suresh Muthukumaraswamy, Harriet de Wit 31 citations

Taking regular low doses of psychedelic drugs (microdosing) is a practice that has drawn recent scientific and media attention for its potential psychotherapeutic effects. Yet, controlled studies evaluating this practice have lagged. Here, we review recent evidence focusing on studies that were conducted with rigorous experimental control. Studies conducted under laboratory settings using...

The effect of psychedelics on the level of brain-derived neurotrophic factor: A systematic review and meta-analysis.

Journal of Psychopharmacology May 1, 2024 Arman Shafiee, Razman Arabzadeh Bahri, Mohammad Ali Rafiei et al. 21 citations Retracted

Recent interest in the potential therapeutic effects of psychedelics has led to investigations into their influence on molecular signaling pathways within the brain. Integrated review and analysis of different studies in this field. A systematic search was conducted across international databases including Embase, Scopus, Web of Science, and PubMed from inception to 9 July 2023. Eligibility...